

Peter P Toth

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/387906/publications.pdf](https://exaly.com/author-pdf/387906/publications.pdf)

Version: 2024-02-01

259
papers

13,527
citations

17587

60
h-index

24864

104
g-index

273
all docs

273
docs citations

273
times ranked

14102
citing authors

#	ARTICLE	IF	CITATIONS
1	Editorial commentary: Is it really a slam-dunk that reducing Lp(a) will decrease risk for cardiovascular events? Not so fast. Trends in Cardiovascular Medicine, 2024, 34, 200-202.	5.2	0
2	Dickkopf-1: an emerging danger signal in hypertension and cardiovascular disease. European Heart Journal, 2024, 45, 704-706.	2.2	0
3	Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. Obesity Pillars, 2024, 10, 100108.	3.3	0
4	New approaches to triglyceride reduction: Is there any hope left?. American Journal of Preventive Cardiology, 2024, 18, 100648.	3.4	1
5	Branched-Chain Amino Acids, Alanine, and Thyroid Function: A Cross-Sectional, Nuclear Magnetic Resonance (NMR)-Based Approach from ELSA-Brasil. Metabolites, 2024, 14, 437.	3.0	0
6	The association between triglyceride-rich lipoproteins, circulating leukocytes, and low-grade inflammation: The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Journal of Clinical Lipidology, 2023, 17, 261-271.	1.5	3
7	Eliminating atherosclerotic cardiovascular disease residual risk. European Heart Journal, 2023, 44, 4731-4733.	2.2	6
8	Coronary heart disease risk: Low-density lipoprotein and beyond. Trends in Cardiovascular Medicine, 2022, 32, 181-194.	5.2	77
9	Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study. Rheumatology International, 2022, 42, 261-271.	3.1	5
10	Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress. Biomarker Insights, 2022, 17, 117727192110667.	2.8	1
11	Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)-Free Low-Density Lipoprotein Cholesterol. Journal of the American Heart Association, 2022, 11, e023136.	3.8	9
12	Cardiac CT angiography in current practice: An American society for preventive cardiology clinical practice statement. American Journal of Preventive Cardiology, 2022, 9, 100318.	3.4	18
13	CAC for Risk Stratification Among Individuals With Hypertriglyceridemia Free of Clinical Atherosclerotic Cardiovascular Disease. JACC: Cardiovascular Imaging, 2022, 15, 641-651.	5.9	13
14	Substantially elevated TSH, not traditional clinical subclinical thyroid disorder groupings, are associated with smaller LDL-P mean size: ELSA-Brasil. Journal of Clinical Lipidology, 2022, , .	1.5	0
15	Contemporary Management of Dyslipidemia. Drugs, 2022, 82, 559-576.	10.8	24
16	President's page: ASPC is leading the way in preventive cardiology. American Journal of Preventive Cardiology, 2022, 9, 100321.	3.4	0
17	Step-by-step diagnosis and management of the nocebo/drugcebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1596-1622.	7.3	42
18	Ten things to know about ten cardiovascular disease risk factors. American Journal of Preventive Cardiology, 2022, 10, 100342.	3.4	41

#	ARTICLE	IF	CITATIONS
19	Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement. <i>American Journal of Preventive Cardiology</i> , 2022, 10, 100335.	3.4	86
20	Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 101161ATV0000000000000153.	3.9	229
21	ASPC president's page: Getting back to basics one patient at a time. <i>American Journal of Preventive Cardiology</i> , 2022, 10, 100350.	3.4	0
22	Differentiating EPA from EPA/DHA in cardiovascular risk reduction. <i>American Heart Journal Plus</i> , 2022, 17, 100148.	0.6	5
23	The Relationship between COVID-19 and Hypothalamicâ€Pituitaryâ€Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excessâ€The CAPISCO International Expert Panel. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7326.	4.1	32
24	There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness. <i>American Journal of Preventive Cardiology</i> , 2022, 12, 100371.	3.4	34
25	Coronary Artery Calcium Score to Refine the Use of PCSK9i in Asymptomatic Individuals: A Multicohort Study. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.8	5
26	LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals. <i>Postgraduate Medicine</i> , 2022, 134, 752-762.	2.0	19
27	Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease. <i>American Journal of Preventive Cardiology</i> , 2022, 11, 100372.	3.4	3
28	Network Metaâ€Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipidâ€Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Lowâ€Density Lipoprotein Cholesterol. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.8	18
29	Physical activity, cardiorespiratory fitness, and cardiovascular health: A clinical practice statement of the American Society for Preventive Cardiology Part II: Physical activity, cardiorespiratory fitness, minimum and goal intensities for exercise training, prescriptive methods, and special patient populations. <i>American Journal of Preventive Cardiology</i> , 2022, 12, 100425.	3.4	20
30	Physical activity, cardiorespiratory fitness, and cardiovascular health: A clinical practice statement of the American Society for Preventive Cardiology Part I: Bioenergetics, contemporary physical activity recommendations, benefits, risks, extreme exercise regimens, potential maladaptations. <i>American Journal of Preventive Cardiology</i> , 2022, 12, 100424.	3.4	31
31	Management of pregnancy-related hypertensive disorders in patients infected with SARS CoV-2: pharmacological and clinical issues. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 346-351.	3.0	3
32	Heart failure with preserved ejection fraction: strategies for disease management and emerging therapeutic approaches. <i>Postgraduate Medicine</i> , 2021, 133, 125-139.	2.0	9
33	Unfavorable Triglyceride-rich Particle Profile in Subclinical Thyroid Disease: A Cross-sectional Analysis of ELSA-Brasil. <i>Endocrinology</i> , 2021, 162, .	2.8	4
34	Impact of Expanded FDA Indication for Icosapent Ethyl On Enhanced Cardiovascular Residual Risk Reduction. <i>Future Cardiology</i> , 2021, 17, 155-174.	1.0	16
35	Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 49-56.	5.2	13
36	Cardiovascular Disease Epidemiology and Risk Factors: General Concepts. <i>Contemporary Cardiology</i> , 2021, , 1-22.	0.0	0

#	ARTICLE	IF	CITATIONS
37	ASPC President's Page: Addressing Unmet Needs in Preventive Cardiology. American Journal of Preventive Cardiology, 2021, 5, 100155.	3.4	0
38	Branched-chain amino acids predict incident diabetes in the Brazilian Longitudinal Study of Adult Health " ELSA-Brasil. Diabetes Research and Clinical Practice, 2021, 174, 108747.	2.8	10
39	INCREASED INPATIENT MORTALITY FOR CARDIOVASCULAR PATIENTS DURING THE FIRST WAVE OF THE COVID-19 EPIDEMIC IN NEW YORK. Journal of the American College of Cardiology, 2021, 77, 3042.	5.5	1
40	ASPC President's Page: Advancing and Refining Cardiovascular Disease Prevention. American Journal of Preventive Cardiology, 2021, 6, 100194.	3.4	0
41	Triglycerides and Atherosclerosis. Journal of the American College of Cardiology, 2021, 77, 3042-3045.	5.5	11
42	Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial. Cardiovascular Diabetology, 2021, 20, 125.	6.8	13
43	Ten things to know about ten imaging studies: A preventive cardiology perspective (ASPC top ten) Tj ETQq1 1 0.784314,rgBT /Over 3.4	3.4	0
44	Low-Density Lipoprotein Cholesterol Treatment Rates in High Risk Patients: More Disappointment Despite Ever More Refined Evidence-Based Guidelines.. American Journal of Preventive Cardiology, 2021, 6, 100186.	3.4	4
45	Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies. BMC Medicine, 2021, 19, 139.	5.6	29
46	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases " A position paper from the International Lipid Expert Panel (ILEP). Progress in Cardiovascular Diseases, 2021, 67, 40-52.	3.6	42
47	Real-world Analyses of Patients With Elevated Atherosclerotic Cardiovascular Disease Risk From the Optum Research Database. Future Cardiology, 2021, 17, 743-755.	1.0	9
48	Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE). Archivos De Cardiologia De Mexico, 2021, 92, .	0.2	5
49	Statin Prescribing and Dosing" Failure Has Become an Option. JAMA Cardiology, 2021, 6, 854.	6.3	1
50	Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial. Journal of Alzheimer's Disease, 2021, 83, 1703-1715.	2.7	16
51	Celebrating ASPC's achievements and introducing new educational offerings. American Journal of Preventive Cardiology, 2021, 7, 100226.	3.4	0
52	That Myalgia of Yours Is Not From Statin" Intolerance. Journal of the American College of Cardiology, 2021, 78, 1223-1226.	5.5	6
53	Hepatic Sensing Loop Regulates PCSK9" Secretion in Response to Inhibitory Antibodies. Journal of the American College of Cardiology, 2021, 78, 1437-1449.	5.5	14
54	Proprotein Convertase Subtilisin/Kexin Type 9: Functional Role in Lipid Metabolism and Its Therapeutic Inhibition. Contemporary Cardiology, 2021, , 269-294.	0.0	0

#	ARTICLE	IF	CITATIONS
55	Atherogenesis and Vascular Biology. Contemporary Cardiology, 2021, , 11-34.	0.0	2
56	The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGRAM 2015 Study. Journal of Clinical Medicine, 2021, 10, 5656.	2.5	11
57	Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel. Frontiers in Cardiovascular Medicine, 2021, 8, 787761.	2.4	41
58	Vitamin D supplementation and incident preeclampsia: A systematic review and meta-analysis of randomized clinical trials. Clinical Nutrition, 2020, 39, 1742-1752.	5.0	118
59	Spotlight from the American Society for Preventive Cardiology on Key Features of the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol. American Journal of Cardiovascular Drugs, 2020, 20, 1-9.	2.3	9
60	Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study. European Journal of Preventive Cardiology, 2020, 27, 1597-1605.	1.8	47
61	Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real-world evidence. Diabetes, Obesity and Metabolism, 2020, 22, 279-289.	4.5	36
62	Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory Cytokines and Hepatic Steatosis in Subjects with the Metabolic Syndrome: A 2-Month Intervention Study. Metabolites, 2020, 10, 392.	3.0	39
63	Differences in HDL particle size in the presence of subclinical thyroid dysfunctions: The ELSA-Brasil study. Atherosclerosis, 2020, 312, 60-65.	0.8	4
64	Targeting hypertriglyceridemia to mitigate cardiovascular risk: A review. American Journal of Preventive Cardiology, 2020, 3, 100086.	3.4	11
65	Inflammation and cardiovascular disease: From mechanisms to therapeutics. American Journal of Preventive Cardiology, 2020, 4, 100130.	3.4	179
66	Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMd dyslipidemia study). Lipids in Health and Disease, 2020, 19, 237.	3.0	9
67	Cardiovascular Risk and Statin Therapy Considerations in Women. Diagnostics, 2020, 10, 483.	2.7	56
68	Identification and treatment of those most at risk for premature atherosclerotic cardiovascular disease: We just cannot seem to get it right. American Journal of Preventive Cardiology, 2020, 2, 100040.	3.4	2
69	Pasta Supplemented with Opuntia ficus-indica Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Patients with Risk Factors for the Metabolic Syndrome: A Four-Week Intervention Study. Metabolites, 2020, 10, 428.	3.0	22
70	Modern prevalence of the Fredrickson-Levy-Lees dyslipidemias: findings from the Very Large Database of Lipids and National Health and Nutrition Examination Survey. Archives of Medical Science, 2020, 16, 1279-1287.	0.9	14
71	REDUCE-IT Eligibility and Preventable Cardiovascular Events in the US Population (from the National) Tj ETQq1 1 0.784314 rgBT /Over 1.5 11	1.5	11
72	Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: Results from National Health and Nutrition Examination Survey (NHANES) 2007-2014. American Journal of Preventive Cardiology, 2020, 3, 100087.	3.4	3

#	ARTICLE	IF	CITATIONS
73	Prevalence of US Adults with Triglycerides ≥ 150 mg/dl: NHANES 2007–2014. <i>Cardiology and Therapy</i> , 2020, 9, 207-213.	2.6	41
74	Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology. <i>American Journal of Preventive Cardiology</i> , 2020, 1, 100009.	3.4	96
75	Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials. <i>Current Atherosclerosis Reports</i> , 2020, 22, 18.	4.7	31
76	Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1565.	6.9	114
77	Nutraceutical support in heart failure: a position paper of the International Lipid Expert Panel (ILEP). <i>Nutrition Research Reviews</i> , 2020, 33, 155-179.	4.6	35
78	Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies. <i>Journal of the American Heart Association</i> , 2020, 9, e014129.	3.8	28
79	Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , 2020, 155, 104719.	7.1	18
80	Recommendations of statin treatment after acute coronary syndrome: Hungarian experiences. <i>Atherosclerosis</i> , 2020, 303, 53-54.	0.8	2
81	Association of types of dietary fats and all-cause and cause-specific mortality: A prospective cohort study and meta-analysis of prospective studies with 1,164,029 participants. <i>Clinical Nutrition</i> , 2020, 39, 3677-3686.	5.0	55
82	The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study. <i>Atherosclerosis Supplements</i> , 2020, 42, e15-e24.	1.4	20
83	Familial Hypercholesterolemia and Lipoprotein(a). <i>Journal of the American College of Cardiology</i> , 2020, 75, 2694-2697.	5.5	2
84	New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease. <i>European Cardiology Review</i> , 2020, 15, 1-9.	2.2	40
85	Weight loss programmes using low carbohydrate diets to control the cardiovascular risk in adolescents (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 90.	1.8	8
86	Design and rationale of a nationwide screening analysis from the LIPIDOGRAM2015 and LIPIDOGEN2015 studies. <i>Archives of Medical Science</i> , 2020, 18, 604-616.	0.9	12
87	The bandwidth of preventive cardiology continues to increase: Meeting the challenge head on. <i>American Journal of Preventive Cardiology</i> , 2020, 4, 100132.	3.4	0
88	Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study. <i>Cardiovascular Research</i> , 2019, 115, 204-212.	3.6	36
89	The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy. <i>Journal of Clinical Lipidology</i> , 2019, 13, 754-761.	1.5	10
90	Hypertriglyceridemia is associated with an increased risk of peripheral arterial revascularization in high-risk statin-treated patients: A large administrative retrospective analysis. <i>Clinical Cardiology</i> , 2019, 42, 908-913.	1.9	11

#	ARTICLE	IF	CITATIONS
91	Comparing different assessments of remnant lipoprotein cholesterol: The very large database of lipids. <i>Journal of Clinical Lipidology</i> , 2019, 13, 634-644.	1.5	33
92	Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis. <i>Lipids in Health and Disease</i> , 2019, 18, 175.	3.0	53
93	High-density Lipoprotein-cholesterol Subfractions and Coronary Artery Calcium: The ELSA-Brasil Study. <i>Archives of Medical Research</i> , 2019, 50, 362-367.	3.5	16
94	Comparing remnant lipoprotein cholesterol measurement methods to evaluate efficacy of ezetimibe/statin vs statin therapy. <i>Journal of Clinical Lipidology</i> , 2019, 13, 997-1007.e8.	1.5	7
95	Relation Between Cardiology Follow-Up Visits, Evidence-Based Statin Prescribing, and Statin Adherence (from the Veterans Affairs Health Care System). <i>American Journal of Cardiology</i> , 2019, 124, 1165-1170.	1.5	7
96	Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1670-1680.	2.8	49
97	Impact of improved low-density lipoprotein cholesterol assessment on guideline classification in the modern treatment era—Results from a racially diverse Brazilian cross-sectional study. <i>Journal of Clinical Lipidology</i> , 2019, 13, 804-811.e2.	1.5	10
98	Therapeutic effects of statins on chromosomal DNA damage of dyslipidemic patients. <i>Experimental Biology and Medicine</i> , 2019, 244, 1089-1095.	2.4	10
99	Changes in lipoprotein subfractions following menopause in the Longitudinal Study of Adult Health (ELSA-Brasil). <i>Maturitas</i> , 2019, 130, 32-37.	2.5	13
100	Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007–2014. <i>Diabetes Care</i> , 2019, 42, 2307-2314.	9.0	47
101	Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. <i>American Heart Journal</i> , 2019, 217, 72-83.	3.0	47
102	Trends in Lipids, Obesity, Metabolic Syndrome, and Diabetes Mellitus in the United States: An NHANES Analysis (2003–2004 to 2013–2014). <i>Obesity</i> , 2019, 27, 309-314.	3.1	100
103	Response to “Trends in Obesity, NHANES 2003–2004 to 2013–2014: Is Waist Circumference Increasing Independently of Body Mass Index?” <i>Obesity</i> , 2019, 27, 1044.	3.1	0
104	Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2019, 143, 1-16.	7.1	101
105	Altlix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study. <i>Nutrients</i> , 2019, 11, 2580.	4.1	42
106	<p>Elevated Triglycerides (≥ 150 mg/dL) and High Triglycerides (200–499 mg/dL) Are Significant Predictors of New Heart Failure Diagnosis: A Real-World Analysis of High-Risk Statin-Treated Patients</p>. <i>Vascular Health and Risk Management</i> , 2019, Volume 15, 533-538.	2.2	13
107	Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey. <i>Journal of Clinical Lipidology</i> , 2019, 13, 100-108.	1.5	58
108	Composite acute phase glycoproteins with coronary artery calcification depends on metabolic syndrome presence – The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>Journal of Cardiology</i> , 2019, 73, 408-415.	1.9	10

#	ARTICLE	IF	CITATIONS
109	Comparing a novel equation for calculating low-density lipoprotein cholesterol with the Friedewald equation: A VOYAGER analysis. <i>Clinical Biochemistry</i> , 2019, 64, 24-29.	2.0	37
110	Management of Dyslipidemia. <i>Contemporary Cardiology</i> , 2019, , 39-69.	0.0	0
111	Lipoprotein Subfractions in Patients with Acute Coronary Syndromes: Should we Reach Beyond LDL-C?. <i>Current Vascular Pharmacology</i> , 2019, 17, 376-378.	1.5	2
112	Prevalence of United States adults with triglycerides \geq 135 mg/dL: NHANES 2007-2014. <i>Cardiology Journal</i> , 2019, 26, 604-606.	1.3	6
113	Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. <i>Kidney International</i> , 2018, 93, 1397-1408.	5.3	85
114	Management of Statin Intolerance in 2018: Still More Questions Than Answers. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 157-173.	2.3	135
115	Relationship between lipoprotein subfraction cholesterol and residual risk for cardiovascular outcomes: A post hoc analysis of the AIM-HIGH trial. <i>Journal of Clinical Lipidology</i> , 2018, 12, 741-747.e11.	1.5	6
116	Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation. <i>Current Atherosclerosis Reports</i> , 2018, 20, 20.	4.7	69
117	Effect of Evolocumab on Lipoprotein Particles. <i>American Journal of Cardiology</i> , 2018, 121, 308-314.	1.5	30
118	Introducing the "Drucebo" effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 1023-1033.	7.3	89
119	High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real-World Administrative Claims Analysis of Statin-Treated Patients With High Residual Cardiovascular Risk. <i>Journal of the American Heart Association</i> , 2018, 7, e008740.	3.8	87
120	Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1966-1976.	1.8	54
121	Association between high-density lipoprotein subfractions and low-grade inflammation, insulin resistance, and metabolic syndrome components: The ELSA-Brasil study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1290-1297.e1.	1.5	11
122	Natural approaches in metabolic syndrome management. <i>Archives of Medical Science</i> , 2018, 14, 422-441.	0.9	104
123	Novel Therapeutic Targets for Managing Dyslipidemia. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 733-747.	8.4	32
124	Polyphenols: Potential Use in the Prevention and Treatment of Cardiovascular Diseases. <i>Current Pharmaceutical Design</i> , 2018, 24, 239-258.	1.8	90
125	Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. <i>Journal of Medical Economics</i> , 2017, 20, 555-564.	2.1	49
126	Lipid-lowering treatment modifications among patients with hyperlipidemia and a prior cardiovascular event: a US retrospective cohort study. <i>Current Medical Research and Opinion</i> , 2017, 33, 869-876.	1.9	5

#	ARTICLE	IF	CITATIONS
127	Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. <i>Circulation</i> , 2017, 135, 1819-1831.	6.2	72
128	Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis. <i>Journal of Clinical Lipidology</i> , 2017, 11, 972-985.e9.	1.5	44
129	The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2017, 122, 105-117.	7.1	22
130	<scp>PCSK9</scp> inhibitor access barriersâ€”issues and recommendations: Improving the access process for patients, clinicians and payers. <i>Clinical Cardiology</i> , 2017, 40, 243-254.	1.9	74
131	Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.8	66
132	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Nutrition Reviews</i> , 2017, 75, 731-767.	5.9	246
133	Association Between Smoking and Serum GlycA and High-â€”sensitivity C-â€”Reactive Protein Levels: The Multi-â€”Ethnic Study of Atherosclerosis (MESA) and Brazilian Longitudinal Study of Adult Health (ELSA-â€”Brasil). <i>Journal of the American Heart Association</i> , 2017, 6, .	3.8	29
134	Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 419-431.	2.8	46
135	Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gaps. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1152-1160.e2.	1.5	85
136	Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2017, 120, 1521-1527.	1.5	37
137	What is sufficient drug therapy for lipoprotein elevations?. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1300-1308.	1.5	0
138	Accuracy of low-density lipoprotein cholesterol estimation at very low levels. <i>BMC Medicine</i> , 2017, 15, 83.	5.6	39
139	All-Cause and Acute Pancreatitis Health Care Costs in Patients With Severe Hypertriglyceridemia. <i>Pancreas</i> , 2017, 46, 57-63.	1.1	9
140	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2017, 5, 965-1005.	0.9	213
141	Nutraceuticals as an Important Part of Combination Therapy in Dyslipidaemia. <i>Current Pharmaceutical Design</i> , 2017, 23, 2496-2503.	1.8	33
142	PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab. <i>Vascular Health and Risk Management</i> , 2016, 12, 185.	2.2	16
143	Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. <i>Vascular Health and Risk Management</i> , 2016, 12, 171.	2.2	175
144	Molecular mechanisms of statin intolerance. <i>Archives of Medical Science</i> , 2016, 3, 645-658.	0.9	58

#	ARTICLE	IF	CITATIONS
145	Systematic Review of Low-Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.8	83
146	IMPROVE-IT. <i>Current Opinion in Cardiology</i> , 2016, 31, 426-433.	1.8	16
147	Does vitamin D supplementation alter plasma adipokines concentrations? A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2016, 107, 360-371.	7.1	62
148	Statin therapy and inflammation in patients with diabetes treated with high dose aspirin. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1365-1370.	2.4	10
149	Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study. <i>Lipids in Health and Disease</i> , 2016, 15, 22.	3.0	25
150	Statin Combination Therapy and Cardiovascular Risk Reduction. <i>Future Cardiology</i> , 2016, 12, 289-315.	1.0	14
151	Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.8	130
152	Bioresorbable scaffold "A magic bullet for the treatment of coronary artery disease?. <i>International Journal of Cardiology</i> , 2016, 215, 47-59.	1.6	25
153	Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 206-212.	3.4	74
154	Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction. <i>American Journal of Cardiology</i> , 2016, 118, 19A-32A.	1.5	8
155	Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia. <i>American Journal of Cardiology</i> , 2016, 118, 1812-1820.	1.5	7
156	The effects of statin treatment on adrenal and sexual function and nitric oxide levels in hypercholesterolemic male patients treated with a statin. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1452-1461.	1.5	18
157	Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. <i>International Journal of Cardiology</i> , 2016, 225, 184-196.	1.6	157
158	Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. <i>Atherosclerosis</i> , 2016, 253, 194-208.	0.8	149
159	An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1248-1258.	1.5	29
160	Implications of the New US Cholesterol Guidelines in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>Clinical Cardiology</i> , 2016, 39, 215-222.	1.9	5
161	Prevalence of potential familial hypercholesterolemia (FH) in 54,811 statin-treated patients in clinical practice. <i>Atherosclerosis</i> , 2016, 252, 1-8.	0.8	27
162	Productivity losses associated with cardiovascular disease: a systematic review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 759-769.	1.4	40

#	ARTICLE	IF	CITATIONS
163	Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. <i>Scientific Reports</i> , 2016, 6, 30060.	3.4	25
164	PCSK9 and Lipoprotein(a). <i>Circulation Research</i> , 2016, 119, 3-6.	6.5	5
165	Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo. <i>Lipids in Health and Disease</i> , 2016, 15, 28.	3.0	39
166	A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients. <i>Pharmacological Research</i> , 2016, 111, 343-356.	7.1	20
167	Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia. <i>Clinical Therapeutics</i> , 2016, 38, 603-609.	2.2	15
168	Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2016, 103, 236-252.	7.1	60
169	Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 41-49.	1.8	68
170	Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. <i>BMC Medicine</i> , 2015, 13, 229.	5.6	177
171	Burden of First and Recurrent Cardiovascular Events Among Patients With Hyperlipidemia. <i>Clinical Cardiology</i> , 2015, 38, 483-491.	1.9	33
172	Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2015, 1, 1-23.	0.9	318
173	Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. <i>Atherosclerosis</i> , 2015, 241, 433-442.	0.8	149
174	The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease. <i>Lipids in Health and Disease</i> , 2015, 14, 29.	3.0	44
175	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 849-854.	1.8	61
176	Is HPS2-THRIVE the death knell for niacin?. <i>Journal of Clinical Lipidology</i> , 2015, 9, 343-350.	1.5	9
177	Lipid phenotypes at the extremes of high-density lipoprotein cholesterol: The very large database of lipids-9. <i>Journal of Clinical Lipidology</i> , 2015, 9, 511-518.e5.	1.5	5
178	Is the Guideline Process Replicable and, if Not, What Does This Mean?. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 3-9.	3.6	2
179	Statin therapy and plasma coenzyme Q10 concentrations – A systematic review and meta-analysis of placebo-controlled trials. <i>Pharmacological Research</i> , 2015, 99, 329-336.	7.1	154
180	Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol. <i>Circulation</i> , 2015, 132, 667-676.	6.2	44

#	ARTICLE	IF	CITATIONS
181	Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. <i>Atherosclerosis</i> , 2015, 242, 87-96.	0.8	47
182	Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study. <i>Atherosclerosis</i> , 2015, 242, 243-250.	0.8	107
183	Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease. <i>Journal of Clinical Lipidology</i> , 2015, 9, 576-582.	1.5	57
184	Relation of Fish Oil Supplementation to Markers of Atherothrombotic Risk in Patients With Cardiovascular Disease Not Receiving Lipid-Lowering Therapy. <i>American Journal of Cardiology</i> , 2015, 115, 1204-1211.	1.5	21
185	Recommendations for the Management of Patients with Familial Hypercholesterolemia. <i>Current Atherosclerosis Reports</i> , 2015, 17, 473.	4.7	13
186	Treatment of Dyslipidemia in Elderly Patients With Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1873-1875.	5.5	5
187	Drug Evaluation: The Combination of Fenofibrate and Simvastatin for the Treatment of Dyslipidemia: When and for Whom?. , 2015, , 179-190.		1
188	Screening and advanced lipid phenotyping in familial hypercholesterolemia: The Very Large Database of Lipids Study-17 (VLDL-17). <i>Journal of Clinical Lipidology</i> , 2015, 9, 676-683.	1.5	14
189	Analysis of vitamin D levels in patients with and without statin-associated myalgia " A systematic review and meta-analysis of 7 studies with 2420 patients. <i>International Journal of Cardiology</i> , 2015, 178, 111-116.	1.6	157
190	HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative. <i>European Heart Journal</i> , 2015, 36, 22-30.	2.2	148
191	Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study. <i>Frontiers in Pharmacology</i> , 2015, 6, 299.	3.6	99
192	Dysfunctional HDL: the journey from savior to slayer. <i>Clinical Lipidology</i> , 2014, 9, 49-59.	0.4	15
193	Narrowing Sex Differences in Lipoprotein Cholesterol Subclasses Following Midlife: The Very Large Database of Lipids (VLDL-4). <i>Journal of the American Heart Association</i> , 2014, 3, e000851.	3.8	55
194	Direct oral anticoagulants as alternative treatment options for the effective long-term treatment of patients with pulmonary embolism in primary care: a review. <i>Annals of Medicine</i> , 2014, 46, 341-352.	3.8	1
195	An Update on the Benefits and Risks of Rosuvastatin Therapy. <i>Postgraduate Medicine</i> , 2014, 126, 7-17.	2.0	15
196	Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 453-461.	4.9	65
197	Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. <i>Journal of Clinical Lipidology</i> , 2014, 8, 148-172.	1.5	101
198	Prevalence of dyslipidemia and associated risk factors in Turkish adults. <i>Journal of Clinical Lipidology</i> , 2014, 8, 206-216.	1.5	101

#	ARTICLE	IF	CITATIONS
199	Residual macrovascular risk in 2013: what have we learned?. <i>Cardiovascular Diabetology</i> , 2014, 13, 26.	6.8	151
200	HDL Hypothesis: Where Do We Stand Now?. <i>Current Atherosclerosis Reports</i> , 2014, 16, 398.	4.7	25
201	Should low high-density lipoprotein cholesterol (HDL-C) be treated?. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 353-368.	4.9	61
202	Clinical and economic outcomes in a real-world population of patients with elevated triglyceride levels. <i>Atherosclerosis</i> , 2014, 237, 790-797.	0.8	17
203	The Therapeutic Role of Niacin in Dyslipidemia Management. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 141-158.	2.1	56
204	The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular disease. <i>Journal of Clinical Lipidology</i> , 2014, 8, 594-605.	1.5	11
205	JCL Roundtable: HDL in the primary care setting. <i>Journal of Clinical Lipidology</i> , 2014, 8, 364-372.	1.5	4
206	Combination therapy in dyslipidemia: Where are we now?. <i>Atherosclerosis</i> , 2014, 237, 319-335.	0.8	39
207	High-density lipoprotein subfractions: current views and clinical practice applications. <i>Trends in Endocrinology and Metabolism</i> , 2014, 25, 329-336.	6.9	43
208	Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. <i>Journal of Clinical Lipidology</i> , 2014, 8, 107-116.	1.5	31
209	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>International Journal of Cardiology</i> , 2014, 171, 309-325.	1.6	321
210	Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. <i>Atherosclerosis</i> , 2014, 235, 585-591.	0.8	56
211	The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. <i>Atherosclerosis Supplements</i> , 2014, 15, 1-15.	1.4	85
212	Insulin Resistance, Small LDL Particles, and Risk for Atherosclerotic Disease. <i>Current Vascular Pharmacology</i> , 2014, 12, 653-657.	1.5	44
213	Use of Microsomal Triglyceride Transfer Protein Inhibitors in Patients With Homozygous Familial Hypercholesterolemia: Translating Clinical Trial Experience Into Clinical Practice. <i>Reviews in Cardiovascular Medicine</i> , 2014, 15, 1-10.	1.3	24
214	High-density lipoproteins: A consensus statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2013, 7, 484-525.	1.5	282
215	Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels From the Standard Lipid Profile. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2061.	6.9	597
216	Non-HDL-C, High-Density Lipoprotein Cholesterol, Guideline Targets, and Population Percentiles for Secondary Prevention in 1.3 Million Adults. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1960-1965.	5.5	61

#	ARTICLE	IF	CITATIONS
217	Friedewald-Estimated Versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications. <i>Journal of the American College of Cardiology</i> , 2013, 62, 732-739.	5.5	341
218	Emerging LDL therapies: Mipomersenâ€”antisense oligonucleotide therapy in the management ofÂhypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2013, 7, S6-S10.	1.5	35
219	Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapyâ€”A meta-analysis of 11 randomized controlled trials involving 21,295 participants. <i>Pharmacological Research</i> , 2013, 72, 35-44.	7.1	92
220	Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2013, 29, 435-451.	1.9	37
221	The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups. <i>Clinical Lipidology</i> , 2013, 8, 13-41.	0.4	24
222	Stroke Prevention in Patients With Atrial Fibrillation: Focus on New Oral Anticoagulants. <i>Postgraduate Medicine</i> , 2013, 125, 155-161.	2.0	1
223	Very Large Database of Lipids: Rationale and Design. <i>Clinical Cardiology</i> , 2013, 36, 641-648.	1.9	39
224	Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. <i>Vascular Health and Risk Management</i> , 2013, 9, 719.	2.2	29
225	Effective Management of the Type 2 Diabetes Patient with Cardiovascular and Renal Disease: Secondary Prevention Strategies after a Myocardial Infarction. <i>Current Diabetes Reviews</i> , 2012, 8, 219-228.	1.3	4
226	Glucolipotoxicity and the Heart. <i>Heart Failure Clinics</i> , 2012, 8, xvii-xviii.	2.3	4
227	Epicardial Steatosis, Insulin Resistance, and Coronary Artery Disease. <i>Heart Failure Clinics</i> , 2012, 8, 671-678.	2.3	16
228	Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effectsÂon low-density lipoprotein-cholesterol reduction. <i>Journal of Clinical Lipidology</i> , 2012, 6, 180-191.	1.5	19
229	The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2012, 11, 109.	6.8	76
230	Ezetimibe therapy: mechanism of action and clinical update. <i>Vascular Health and Risk Management</i> , 2012, 8, 415.	2.2	174
231	Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy. <i>Vascular Health and Risk Management</i> , 2012, 8, 39.	2.2	24
232	Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. <i>Journal of Clinical Lipidology</i> , 2011, 5, 133-140.	1.5	592
233	Familial Hypercholesterolemias: Prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2011, 5, S9-S17.	1.5	299
234	Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. <i>Journal of Clinical Lipidology</i> , 2011, 5, S1-S8.	1.5	417

#	ARTICLE	IF	CITATIONS
235	Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. <i>Journal of Clinical Lipidology</i> , 2011, 5, 338-367.	1.5	240
236	Antisense therapy and emerging applications for the management of dyslipidemia. <i>Journal of Clinical Lipidology</i> , 2011, 5, 441-449.	1.5	24
237	Drug safety evaluation of rosuvastatin. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 969-986.	2.4	28
238	Pleiotropic Effects of Angiotensin Receptor Blockers: Addressing Comorbidities by Optimizing Hypertension Therapy. <i>Journal of Clinical Hypertension</i> , 2011, 13, 42-51.	2.2	7
239	Update on the efficacy and safety of combination ezetimibe plus statin therapy. <i>Clinical Lipidology</i> , 2010, 5, 655-684.	0.4	33
240	Activation of intracellular signaling systems by high-density lipoproteins. <i>Journal of Clinical Lipidology</i> , 2010, 4, 376-381.	1.5	16
241	Drug Treatment of Hyperlipidaemia. <i>Drugs</i> , 2010, 70, 1363-1379.	10.8	43
242	Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. <i>Vascular Health and Risk Management</i> , 2010, 6, 1065.	2.2	10
243	The Potential Role of Prasugrel in Secondary Prevention of Ischemic Events in Patients with Acute Coronary Syndromes. <i>Postgraduate Medicine</i> , 2009, 121, 59-72.	2.0	5
244	Drug therapy for hypertriglyceridemia: Fibrates and omega-3 fatty acids. <i>Current Atherosclerosis Reports</i> , 2009, 11, 71-79.	4.7	32
245	When high is low: Raising low levels of high-density lipoprotein cholesterol. <i>Current Cardiology Reports</i> , 2008, 10, 488-496.	2.8	13
246	A Commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia) therapy for dyslipidemia?. <i>Journal of Clinical Lipidology</i> , 2008, 2, 313-317.	1.5	20
247	Making a Case for Quantitative Assessment of Cardiovascular Risk. <i>Journal of Clinical Lipidology</i> , 2007, 1, 234-241.	1.5	20
248	Adiponectin and high-density lipoprotein: a metabolic association through thick and thinThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. <i>European Heart Journal</i> , 2005, 26, 1579-1581.	2.2	20
249	The "Good Cholesterol". <i>Circulation</i> , 2005, 111, e89-91.	6.2	79
250	High-Density Lipoprotein and Cardiovascular Risk. <i>Circulation</i> , 2004, 109, 1809-1812.	6.2	116
251	Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. <i>Clinical Therapeutics</i> , 2004, 26, 1355-1367.	2.2	113
252	C-reactive protein and risk of cardiovascular disease: Evidence and clinical application. <i>Current Atherosclerosis Reports</i> , 2003, 5, 341-349.	4.7	93

#	ARTICLE	IF	CITATIONS
253	Reverse cholesterol transport: High-density lipoprotein's magnificent mile. <i>Current Atherosclerosis Reports</i> , 2003, 5, 386-393.	4.7	69
254	High-density lipoprotein: Epidemiology, metabolism, and antiatherogenic effects. <i>Disease-a-Month</i> , 2001, 47, 365-416.	1.2	23
255	The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease. <i>European Cardiology Review</i> , 0, 18, .	2.2	4
256	2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?. <i>Archives of Medical Science</i> , 0, , .	0.9	4
257	It is Time to Address the Contribution of Cholesterol in all APOB-Containing Lipoproteins to Atherosclerotic Cardiovascular Disease. <i>European Heart Journal Open</i> , 0, , .	2.3	0
258	Risk of adverse cardiovascular events based on common genetic variants in 8-year follow-up of the LIPIDOGEN2015 population using the polygenic risk score (PRS) - study design and methodology.. <i>Archives of Medical Science</i> , 0, , .	0.9	0
259	Closing the gap between guidelines and clinical practice for managing dyslipidemia: where are we now?. <i>Expert Review of Cardiovascular Therapy</i> , 0, , 1-17.	1.5	0